## Yang Meng

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8074813/publications.pdf

Version: 2024-02-01

430874 580821 1,393 25 25 18 h-index citations g-index papers 25 25 25 2233 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. Journal of Medical Economics, 2020, 23, 967-977.	2.1	13
2	A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?. Journal of Medical Economics, 2019, 22, 205-214.	2.1	17
3	The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England. European Journal of Health Economics, 2018, 19, 1163-1172.	2.8	25
4	Patient-reported health state utilities in metastatic gastroenteropancreatic neuroendocrine tumours $\hat{a} \in \mathbb{C}$ an analysis based on the CLARINET study. Health and Quality of Life Outcomes, 2017, 15, 131.	2.4	12
5	Developing policy analytics for public health strategy and decisionsâ€"the Sheffield alcohol policy model framework. Annals of Operations Research, 2016, 236, 149-176.	4.1	15
6	Estimated Effects of Different Alcohol Taxation and Price Policies on Health Inequalities: A Mathematical Modelling Study. PLoS Medicine, 2016, 13, e1001963.	8.4	98
7	Estimating under―and over―eporting of drinking in national surveys of alcohol consumption: identification of consistent biases across four Englishâ€speaking countries. Addiction, 2016, 111, 1203-1213.	3.3	85
8	The Sheffield Alcohol Policy Model - A Mathematical Description. Health Economics (United Kingdom), 2015, 24, 1368-1388.	1.7	36
9	A systematic review and economic evaluation of intraoperative tests [RD-100i one-step nucleic acid amplification (OSNA) system and Metasin test] for detecting sentinel lymph node metastases in breast cancer. Health Technology Assessment, 2015, 19, 1-216.	2.8	33
10	Potential benefits of minimum unit pricing for alcohol versus a ban on below cost selling in England 2014: modelling study. BMJ, The, 2014, 349, g5452-g5452.	6.0	54
11	Alcohol tax pass-through across the product and price range: do retailers treat cheap alcohol differently?. Addiction, 2014, 109, 1994-2002.	3.3	44
12	Trend analysis and modelling of genderâ€specific age, period and birth cohort effects on alcohol abstention and consumption level for drinkers in <scp>G</scp> reat <scp>B</scp> ritain using the <scp>G</scp> eneral <scp>L</scp> ifestyle <scp>S</scp> urvey 1984–2009. Addiction, 2014, 109, 206-215.	3.3	107
13	Estimation of usual occasion-based individual drinking patterns using diary survey data. Drug and Alcohol Dependence, 2014, 134, 136-143.	3.2	9
14	Cost-Effectiveness of Cilostazol, Naftidrofuryl Oxalate, and Pentoxifylline for the Treatment of Intermittent Claudication in People With Peripheral Arterial Disease. Angiology, 2014, 65, 190-197.	1.8	18
15	Effects of minimum unit pricing for alcohol on different income and socioeconomic groups: a modelling study. Lancet, The, 2014, 383, 1655-1664.	13.7	235
16	Estimation of own and cross price elasticities of alcohol demand in the UK—A pseudo-panel approach using the Living Costs and Food Survey 2001–2009. Journal of Health Economics, 2014, 34, 96-103.	2.7	68
17	Adjusting for Unrecorded Consumption in Survey and per Capita Sales Data: Quantification of Impact on Gender- and Age-specific Alcohol-attributable Fractions for Oral and Pharyngeal Cancers in Great Britain. Alcohol and Alcoholism, 2013, 48, 241-249.	1.6	41
18	Authors' reply: Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630–1638). British Journal of Surgery, 2013, 100, 1838-1839.	0.3	2

## YANG MENG

#	Article	IF	CITATION
19	Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. British Journal of Surgery, 2012, 99, 1630-1638.	0.3	94
20	Cost-effectiveness of MRI and PET imaging for the evaluation of axillary lymph node metastases in early stage breast cancer. European Journal of Surgical Oncology, 2011, 37, 40-46.	1.0	30
21	Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2011, 37, 187-198.	1.0	112
22	Magnetic resonance for assessment of axillary lymph node status in early breast cancer: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2011, 37, 928-936.	1.0	79
23	Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation. Health Technology Assessment, 2011, 15, iii-iv, 1-134.	2.8	86
24	A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease Health Technology Assessment, 2011, 15, 1-210.	2.8	48
25	An application of agent-based simulation to the management of hospital-acquired infection. Journal of Simulation, 2010, 4, 60-67.	1.5	32